Frequently Asked Questions About CaPTC
What is the Prostate Cancer Transatlantic Consortium (CaPTC)?
The primary goal of CaPTC is to implement transatlantic education, research, training, community service, and policy initiatives that will address the globally disproportionate prostate cancer morbidity and mortality among Black men. Immediate program goals are to:
- explore and quantify the magnitude of prostate cancer morbidity and mortality variance among Black men of African ancestry;
- explore genetic, environmental, and behavioral etiology of this variance; and
- develop community-sensitive initiatives to control prostate cancer.
When was CaPTC formed?
CaPTC was formed in 2005 by Folakemi Odedina, Ph.D., a prostate cancer scientist in Florida.
Who are members of CaPTC?
Members of CaPTC include scientists, clinicians/health care providers, advocates, survivors, and policy makers from Africa, the Caribbean, Europe, and North America.
Who can join CaPTC?
Anyone who is interested in eliminating the worldwide disproportionate burden of prostate cancer in Black men can join.
What are the benefits of joining CaPTC?
There are a numerous benefits:
- provides opportunities for mutual learning, knowledge transfer, and collaborations among prostate cancer scientists, clinicians, survivors, and advocates;
- promotes transdisciplinary and multidisciplinary prostate cancer research globally;
- facilitates networking among individuals involved in all aspects of prostate cancer control, education, and research in Black men.
- facilitates the development of a global community of practice to address common challenges in prostate cancer, including prevention, detection, diagnosis, treatment, and survivorship; and
- contributes to a global impact against prostate cancer through research training and education programs for low-resource countries.
How can I join CaPTC?
There is no fee to join CaPTC. You can become a member by completing the online CaPTC membership form.